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3180Objective: Generating myocyte grafts that bridge across infarcts could maximize their functional impact and
best utilize small numbers of stem cells. To date, however, graft survival within acute infarcts has not been
feasible. To enhance intrainfarct graft viability, human embryonic stem cell–derived cardiomyocytes (hESC-
CMs) were pretreated before implantation with cobalt protoporphyrin (CoPP), a pharmacologic inducer of cy-
toprotective heme oxygenase-1.
Methods: After preculturing with CoPP (vs phosphate-buffered saline), hESC-CMs were injected intramyocar-
dially into acutely infarcted rat hearts, using directed injections to span the infarct. A further group received
CoPP-pretreated hESC-CMs plus 4 weekly doses of systemic CoPP to prolong exposure to cytoprotectants.
Two control groups with infarcts received vehicle-only intramyocardial injections or weekly systemic CoPP
without cell therapy. Postinfarct ventricular function was gauged by echocardiography and graft size quantified
at 8 weeks by histomorphometry.
Results: CoPP-preconditioned hESC-CMs formed stable grafts deep within infarcted myocardium, while grafts
without CoPP exposure survived mainly at the infarct periphery. Fractional shortening was improved at 4 and 8
weeks in all hearts receiving cell therapies (P<.01 vs vehicle-only injections). CoPP treatment of both graft
hESC-CMs and recipient animals resulted in the largest grafts, highest fractional shortening, preserved wall
thickness, and reduced infarct dimensions.
Conclusions: Cellular therapy delivered acutely after infarction significantly improved postinfarct ventricular
function at 1 and 2 months. CoPP pretreatment of cells resulted in stable hESC-CM grafts within infarcted
myocardium. This design enables construction of directionally oriented, infarct-spanning bands of new
cardiomyocytes that might further improve functional restoration as engrafted myocytes proliferate and mature.
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The Journal of Thoracic and Cardiovascular SurIn the normal heart, ventricular cardiomyocytes are organized
into macroscopic helical myocardial bands that produce the
twisting systolic movement, or torsional deformation, of the
left ventricle during contraction.1-4 Myocardial infarction
(MI) destroys these oriented myocardial fibers, damaging
the structural architecture of the ventricle. Current
intramyocardial cell delivery techniques produce discon-
nected clusters of randomly oriented grafts. We examined
whether, instead, it would be possible to generate band-like
cardiomyocyte grafts to span the infarct area. Such graft
bridges could reconnect the inherent ventricular myocardial
bands still present at the infarct borders, thus maximizing
the functional contribution of the new cells.
However, a major limitation for cell-based therapies is that
only 10% to 20% of injected cells survive implantation
into ischemic infarcts, with most cell loss occurring
within the first week.5-8 Graft cell survival within an
acute infarct has not previously been a realistic expec-
tation5,6,9,10 and, consequently, cell injections are
commonly delivered into peri-infarct areas.7,11,12 The
goal of the present study was to determine whether
pharmacologic induction of survival factors could improve
graft survival within the infarct, which, in turn, would allow
construction of infarct-spanning cellular bridges.gery c December 2014
Abbreviations and Acronyms
CoPP ¼ cobalt protoporphyrin
FS ¼ fractional shortening
hESC-CMs ¼ human embryonic stem cell–derived
cardiomyocytes
HO-1 ¼ heme oxygenase-1
LVEDD ¼ left ventricular end-diastolic
dimension
LVESD ¼ left ventricular end-systolic
dimension
MI ¼ myocardial infarction
SFM ¼ serum-free medium
Luo et al Evolving Technology/Basic ScienceOur group has previously shown that pretreating cardio-
myocyte grafts with cobalt protoporphyrin (CoPP) markedly
improves their survival after implantation into an ischemic
environment.12,13 CoPP activates the transcription factor,
nrf2, which initiates transcription of cytoprotective heme
oxygenase-1 (HO-1) and additional antioxidative fac-
tors.14,15 Preemptive HO-1 induction by gene therapy has
been shown to reduce infarct size, myocyte apoptosis, and
remodeling in hearts subjected to myocardial infarction.16-19
The downstream end products of HO-1, bilirubin and carbon
monoxide, are antiapoptotic, antioxidative, proangiogenic,
and antifibrotic20,21—all desirable attributes for cell therapy
in ischemic beds. In these experiments, we applied
ex vivo CoPP treatment to human embryonic stem cell–
derived cardiomyocytes (hESC-CMs), a cell population
with potential use in clinical cell therapy. Our laboratory
has found that exposing hESC-CMs to a single dose of
CoPP produces sustained HO-1 upregulation for at least 4
days.12 Thus, ex vivo CoPP pretreatment of cells prior to
implantation would, potentially, provide grafted cells with
a survival advantage during the critical first few days
following implantation. Besides CoPP pretreatment of graft
cells, a month-long course of systemic CoPP was adminis-
tered to some recipient groups as a means to extend the
pharmacologic effects during early infarct maturation.E
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Preparation and Characterization of hESC-CMs
HESC-CMs were generated from the H7 human embryonic stem cell
line22 by serial application of activin A (R&D Systems, Minneapolis,
Minn) and BMP4 (R&D Systems),10 omitting the ‘‘pro-survival’’ cocktail
and Percoll gradient centrifugation.12 Spontaneous contraction was observed
after additional culture in RPMI-B27 serum-freemedium (SFM) (Invitrogen,
Carlsbad, Calif). For HO-1 induction, the cell culture medium was
supplemented with 25 mM CoPP (Frontier Scientific Inc, Logan, Utah) in
phosphate-buffered saline (PBS, Invitrogen). Control hESC-CMs were
cultured in media supplemented with PBS alone. Cells were then
enzymatically dispersed and cryopreserved until implantation.
To characterize cells just prior to implantation, aliquots from each
thawed cell batch (Video 1) were plated and fixed with methanol for immu-
nocytochemical profiling. Nascent cardiomyocytes were identified withThe Journal of Thoracic and Carantibodies to cardiac troponin I (Abcam, San Francisco, Calif) and human
Nkx2.5 (R&D Systems), an early cardiac-specific transcription factor;
mitotic cells with antibody to Ki67 (Abcam); and endothelial cells with
antibody to human CD31 (Dako Inc, Carpinteria, Calif). Nuclei were
counterstained with Hoechst 33342 dye (Invitrogen).
Permanent MI Model
Animal protocols were approved by the Institutional Animal Care and
Use Committee and conducted in accordance with the Guide for the Care
and Use of Laboratory Animals (National Research Council 2011). Rats
were placed under isoflurane anesthesia and mechanically ventilated for
MI surgery. Through a left thoracotomy, the left anterior descending coro-
nary arterywas permanently ligatedwithout reperfusion. Fiveminutes after
coronary ligation, microspheres, cells, or media were injected into the
infarct, followed by chest closure and recovery from anesthesia.
Microsphere Retention After Intramyocardial
Injection
Microspheres, equivalent in size to hESC-CMs, were injected into acute
MIs to model immediate cell loss from leakage and washout after direct
intramyocardial injection. In 5 Fischer 344 rats (Charles River
Laboratories, Portage, Mich), 5 3 106 Hydro-Coated Yellow E-Z Trac
Ultraspheres (15-mmdiameter; InteractiveMedicalTechnology, Irvine,Calif)
suspended in 70 mL RPMI were injected into the infarct centers; the heart,
lung, and spleen were excised 15 minutes later. In heart specimens, yellow
microspheres were imaged by dark field epi-illumination under fluorescence
stereomicroscopy (Leica Microsystems, Wetzlar, Germany). Whole hearts,
lungs, and spleenswere placed into individual centrifuge tubes towhich equal
numbers of Pink E-ZTrac Ultraspheres (53 106 in 70 mLRPMI) were added
as the standard for 100% recovery. After microsphere extraction, the relative
proportion of injected (yellow) to standard (pink)microspheres in each organ
was quantified by flow cytometry.
Implantation of hESC-CMs Into Infarcted Hearts
For implantation, 1 3 107 hESC-CMs, suspended in 100 mL RPMI
SFM, were loaded into a 0.3-mL syringe with a 29-gauge needle for
intrainfarct injection into athymicmale rats (NIH-Whn, 240-280 g; Taconic
Farms, Cambridge City, Ind). To produce a band of cells across the infarct,
the needle was inserted from each of the 2 infarct margins, converging at
the infarct center, creating a track that spanned the infarct from 1 uninjured
edge to the other (Video 2). Cells were delivered as the needle was
withdrawn from the myocardium,23 rather than during needle insertion,
to facilitate even distribution along the needle track.
Treatment Groups
Athymic rats, all with acute infarcts, were randomized into 5 treatment
groups (n¼ 8/group). Three cell treatment groups received intrainfarct injec-
tionsof hESC-CMs:group1, hESC-CMspretreatedexvivowithPBS; group2,
hESC-CMs pretreated ex vivo with 25 mMCoPP for 24 hours before implan-
tation; and group 3, hESC-CMs pretreated with CoPP plus recipient rat treat-
ment with a 4-week course of systemic CoPP (5 mg/kg/dose intraperitoneally,
delivered 24 hours before surgery, then onceweekly). Two rats died following
surgery (1 each from groups 1 and 2) and were replaced; all were included in
the baseline data. Two control groups did not receive cell therapy. Of these, 1
control group (group 4) received intrainfarct injections of vehicle (SFM)alone,
while the second control group (group 5) received the 4-week course of sys-
temic CoPP but without cell therapy. This intraperitoneal dose of CoPP,24-26
given weekly,27 produces sustained HO-1 upregulation in heart tissue.
Echocardiography
Two-dimensional M-mode echocardiograms were performed under
isoflurane anesthesia 24 hours before surgery (preinfarction baseline) and
at 48 hours, 4 weeks, and 8 weeks after surgery (M-Turbo; SonoSite, Inc,diovascular Surgery c Volume 148, Number 6 3181
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left ventricular end-diastolic (LVEDD) and end-systolic (LVESD)
dimensions as [(LVEDD  LVESD)/LVEDD]3 100.
Histologic Evaluation of hESC-CM Grafts
At 8 weeks after surgery, hearts were excised, fixed in methyl Carnoy’s
solution, paraffin embedded, and sectioned at 1-mm intervals between the
coronary ligation site and ventricular apex. Serial 5-mm-thick sections
within each macrosection were treated with hematoxylin and eosin and
Masson’s trichrome stains. Human cellular grafts were identified with
antibodies to the b-myosin heavy chain isoform (ATCC, Manassas, Va),
which is preferentially expressed in human, but not rat, myocardium6,10
and with human-specific antibody to lamin A/C (Millipore, Billerica,
Mass).28 Gap junctions were labeled with antibodies to connexin
43 (Cell Signaling, Danvers, Mass). Nuclei were counterstained with
Hoechst dye.
Morphometric Assessments
Morphometry was performed on 4 transverse macrosections per heart,
encompassing the entire infarct. Planimetry was performed using ImageJ
(National Institutes of Health, Bethesda, Md), utilizingMasson’s trichrome
staining, which delineates fibrillar collagen, to define the infarct. Infarct
size was quantified as the mean percentage of left ventricular
circumference occupied by the trichrome blue-positive infarct zone29-31
over all sections for each heart. Infarct wall thickness was calculated as
the mean of 3 measurements taken across the infarct, divided by the
mean of 2 measurements of the noninfarcted adjacent ventricular wall.32
Graft size was measured as the cumulative sum of b-myosin heavy
chain-positive areas on these same standardized sections. The percentage
of grafted area within the infarct was quantified as the sum of grafted areas
surrounded by collagen-rich infarct tissue on each section divided by the
total graft area. The extent of infarct replacement by grafted cells was
determined as the percentage of the total infarct area occupied by human
lamin A/C-positive graft cells.
Statistical Analysis
Data are expressed as means  standard deviations. One-way analyses
of variance with post hoc Bonferroni corrections were used to assess single
outcome measures among treatment groups at the 8-week time point. Sig-
nificance levels were adjusted to P<.017 (0.05 divided by 3) and<.005
(0.05 divided by 10) for comparisons among 3 and 5 treatment groups,
respectively. Analysis of longitudinal echocardiographic data was per-
formed in R statistical software (The R Project for Statistical Computing;
available at: www.r-project.org) using the Laird-Ware mixed effects
model.33 The model was fitted with indicator variables for the 5 treatment
groups and 4 measurement points and 12 two-way interaction terms be-
tween these variables, and included the random effect of animal identifica-
tion number to estimate the variability caused by individuals. Two-way
analyses of variance were used to evaluate 4 outcome variables with Bon-
ferroni multiple testing corrections, using P<.0125 (0.05 divided by 4) to
determine significance.RESULTS
Characterization of Injectates Prior to Implantation
Cardiomyocytes (cardiac troponin I-positive) comprised
64%  4% of cells across all aliquots (Figure E1, A).
Twenty-seven percent  6% of cells stained positively for
the cardiac-specific transcription factor, Nkx2.5, indicating
some cardiomyocytes still in an early phase of differentia-
tion; 15%  8% of cells were Ki67-positive, denoting
a mitotic population (Figure E1, B and C). Human3182 The Journal of Thoracic and Cardiovascular Surendothelial-like cells (hCD31-positive) were rare (<0.1%;
data not shown). No difference in cell composition was
seen between CoPP-pretreated and PBS-pretreated
injectates.
Injectate Retention Within the Heart After
Intrainfarct Injection
Recovery of cell-sized microspheres was used to estimate
the extent of immediate cell loss after intrainfarct injection.
Fifteen minutes after delivery, 68%  16% of injected
microspheres were retained within the heart, the majority
situated along the needle injection track (Figure 1); 10%
 5% had dispersed to the lungs (P<.0001 vs heart spec-
imens), and no signal was detected in the spleen (0.001 
0.001, P< .0001 vs heart specimens). Immediate micro-
sphere loss (and, hence, expected cell loss) through leakage
and intramyocardial collateral flow thus totaled about 30%
of the injectate, with the redistribution primarily into the
pulmonary, not the systemic, circulation.
Graft Histology at 8 Weeks Postimplant
At 8 weeks after implantation, surviving hESC-CM
grafts were found in all hearts receiving hESC-CM
injections (Figure 2, B-G), corroborated by b-myosin heavy
chain immunostaining (Figure 2, H). Immunostaining with
human-specific lamin A/C further confirmed these grafts to
be of human origin (Figure 2, I). By this point, gap junction
proteins were well expressed within the grafts (Figure 2, J).
Grafts of CoPP-Pretreated hESC-CMs Are
Primarily Located Within the Infarct Center
What most distinguished CoPP-pretreated hESC-CM
grafts from PBS-pretreated controls was the extent to which
cells engrafted within the infarct center (Figure 3, A). By 8
weeks postimplant, three quarters of the total graft area in
CoPP-pretreated grafts was located deep within the infarct
(76%  9% for CoPP-pretreated grafts; 77%  12% for
CoPP-pretreated grafts plus systemic CoPP). In contrast,
surviving PBS-pretreated hESC-CMs were found primarily
at the infarct margins with just 38% 11% of the graft area
within the infarct center (P<.0001 vs each CoPP-treated
group).
Adding Systemic CoPP Increases Graft Size at 8
Weeks
At 8 weeks, the rats receiving CoPP-pretreated
hESC-CMs plus a 4-week course of systemic CoPP had
larger cumulative graft areas (0.19 0.02 mm2), effectively
double those in the 2 other cell therapy groups (P<.0001 vs
each group; Figure 3, B). Without systemic CoPP, graft
sizes in hearts receiving CoPP-pretreated hESC-CMs
were similar to those receiving PBS-pretreated cells
(0.10  0.03 mm2 vs 0.11  0.00 mm2, respectively;
P ¼ .67).gery c December 2014
FIGURE1. Microsphere biodistribution after intrainfarct injection. Representative example of an infarcted heart 15minutes after intramyocardial injection
of yellow fluorescent microspheres. A-C, Gross specimen showing the anterior left ventricle with infarct (circled). Black trianglesmark ligation sites on the
left anterior descending and diagonal coronary arteries. White arrows indicate the direction of transinfarct needle injection. C, Blue arrows point to the
majority of the microspheres, which remain within the infarct along the injection tract, effectively spanning the infarct. D-F, Consecutive cross-sections
through the same heart illustrating the microspheres within the mid-level sections. A and D, Dark field epi-illumination images; B and E, fluorescence
imaging to visualize microspheres; C and F, merged images. Scale bar ¼ 5 mm. G, Relative microsphere retention in heart, lung, and spleen as quantified
by flow cytometry (n ¼ 5). ***P<.0001 versus lung or spleen.
Luo et al Evolving Technology/Basic ScienceCoPP Treatment Increases Infarct Replacement by
Engrafted Cells
Planimetry revealed that a larger percentage of the infarct
area was composed of graft cells in hearts receiving
CoPP-pretreated versus PBS-pretreated hESC-CMs (8.2%
 0.8% vs 6.1%  1.0%; P<.001; Figure 3, C). Infarct
replacement by graft cells was further increased when
CoPP pretreatment of the graft was combined with a
4-week course of systemic CoPP (9.7%  0.8%, P<.01
vs CoPP-pretreated, and P<.0001 vs PBS-pretreated grafts;
Figure 3, C).E
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Pretreated hESC-CMs
Histomorphometry at 8 weeks revealed that infarct sizes
ranged from 29%  3% to 37%  3% of the ventricular
circumference across all groups, confirming that all hearts
had sustained substantial infarction. Infarct size was not
altered by cell therapy alone, as the infarct sizes in the
hearts with PBS-pretreated hESC-CMs (35.2%  2.5%)
were not smaller than in hearts receiving vehicle-only
(SFM) injections (37.2% 3.0%, P>.9999). Also, a tran-
sient, 4-week course of systemic CoPP, by itself, did not
affect infarct size at 8 weeks (37.1%  3.0%, P>.9999
vs vehicle-only controls). In contrast, however, infarct sizes
were markedly reduced in both groups receiving CoPP-The Journal of Thoracic and Carpretreated hESC-CMs. In hearts receiving CoPP-
pretreated hESC-CMs alone, infarct size was limited to
32.4%  2.5% of the ventricular circumference (P 
.02 vs each of the 2 groups without cell therapy). Adding
a 4-week course of systemic CoPP to CoPP-pretreated
hESC-CM injections produced a further decrease in the
infarct area to 29.1%  3.0% of the ventricle
(P < .0001 vs the 2 groups without cell therapy and
P ¼ .001 vs hearts with PBS-pretreated hESC-CMs;
Figure 3, D).Cell Therapy With CoPP-Pretreated hESC-CMs
Preserves Infarct Wall Thickness
Marked wall thinning was seen in infarcted hearts that
received vehicle-only injections, reducing ventricular wall
thickness to 43.1% 4.0% of that in adjacent, uninfarcted
heart wall (Figure 3, E). Cell therapy with PBS-pretreated
hESC-CMs did not improve wall thickness at 8 weeks
(45.3%  3.0%, P>.9999 vs each of the 2 control groups
without cell therapy). Also, a 4-week course of systemic
CoPP alone (without cell therapy) did not improve wall
thickness (43.7%  3.5%, P > .9999 vs vehicle-only
controls).
In contrast, wall thickness was much better preserved
in hearts receiving CoPP-pretreated hESC-CM grafts,
with or without systemic CoPP supplementation. Infarctdiovascular Surgery c Volume 148, Number 6 3183
FIGURE 2. Histology of human embryonic stem cell–derived cardiomyocyte (hESC-CM) grafts at 8 weeks after transinfarct implantation. A, Sectioning
diagram for fixed hearts to survey the infarct for the presence of human grafts along the diagonally oriented injection tract. Further serial sectioning was
performed within each region to determine the extent of human cell engraftment in the infarct center (eg, levels 1 and 2). Hematoxylin and eosin staining of
representative hearts from (B-D) the group that received phosphate-buffered saline (PBS)–pretreated hESC-CMs [PBS (g)] and (E-G) the group that
received cobalt protoporphyrin (CoPP)-pretreated hESC-CMs plus recipient treatment with systemic CoPP [CoPP (gþr)]. B and E, In basal regions,
hESC-CM grafts in both treatment groups are seen extending into noninfarcted host myocardium. Note the lack of fibrotic encapsulation around the grafts.
C and F, In the mid-infarct region, grafts are found at the lateral infarct margins, near the infarct border zone, under both experimental conditions (level 1).
However, grafts are present in the infarct center only in (F) the CoPP-treated group, where the potential for infarct replacement by graft and the creation of
infarct-spanning bridges is evident. D and G, In deeper levels of the infarct (level 2), grafts are seen only in the CoPP-treated heart, with no graft present in
the heart that received PBS-treated cells. Grafts were confirmed to be of human origin by immunostaining with (H) b-myosin heavy chain (dark brown)
and (I) human lamin A/C (green). J, Dual immunostaining demonstrating gap junction proteins (connexin 43, red) on graft cells (human lamin A/C, green),
with yellow indicating color convergence. Scale bars¼ 500 mm, 50 mm, 25 mm, and 5 mm, for B-G, H, I, and J, respectively. LAD, Left anterior descending
coronary artery.
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FIGURE 3. Left ventricular morphometry at 8 weeks after acute infarction and cell therapy. A, Percentage of the total graft area located within the infarct.
B, Mean graft areas cumulative over all surveyed sections/heart. C, Extent of total infarct area replaced by cellular graft. A-C, *P<.01; **P<.001;
***P<.0001 between indicated groups. D, Infarct size quantified as a percentage of the total left ventricular circumference. *P<.02 versus SFM and
CoPP(r); ***P  .0001 versus SFM, CoPP(r), and PBS(g). E, Mean wall thickness in the infarct area as a percentage of the wall thickness in the adjacent,
noninfarcted left ventricle. *P<.002 versus SFM and CoPP(r); ***P<.0001 versus SFM, CoPP(r), and PBS(g). Data represent mean values  standard
deviations; n ¼ 8/group. Treatment groups—postinfarct cell therapies: PBS(g), Graft human embryonic stem cell–derived cardiomyocytes (hESC-CMs)
pretreated with phosphate-buffered saline; CoPP(g), graft hESC-CMs pretreated with cobalt protoporphyrin (CoPP); CoPP(gþr), graft hESC-CMs
pretreated with CoPP plus recipient treatment with systemic CoPP. Control groups without cell therapy: SFM, Infarct injections with serum-free media
(vehicle-only control); CoPP(r), infarct recipients treated with systemic CoPP.
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CoPP-pretreated hESC-CMs (P  .002 vs the 2 groups
without cell therapy, and P ¼ .03 vs hearts with
PBS-pretreated cells). In the group that received
CoPP-pretreated hESC-CMs plus systemic CoPP, wall
thickness was maintained at 55.1%  4.0% of normal
(P< .0001 vs the same 3 groups). Infarct areas in hearts
that received CoPP-pretreated hESC-CMs plus systemic
CoPP appeared well populated with cardiomyocytes, with
resident cells consisting not only of graft cells but also of
surviving native cardiomyocytes (Figure 2, F).
Cell Therapy Improves Postinfarct Global Heart
Function
Global heart function, gauged by mean FS, decreased
precipitously in all hearts within 48 hours after infarct
creation (from a mean of 51.6%  6.7% pre-MI to
25.5%  4.9% at 48 hours post-MI; Figure 4, A). In hearts
receiving vehicle-only injections, the FS continued to
decline by another 30% to 35% over the first month
postinfarct, reaching 17.4%  3.5% at 8 weeks
(P ¼ .001 at 4 weeks and P ¼ .015 at 8 weeks vs 48 hours
post-MI). In contrast, FS in all 3 groups of hearts receiving
cell therapy at the time of infarction showed a 13% to 18%
improvement by 4 and 8 weeks, with mean FS at 8 weeks
increasing to 28.2% 5.7%. FS in each cell therapy groupThe Journal of Thoracic and Carwas notably higher than in the vehicle-only (SFM) group at
both 4 weeks (P  .0001) and 8 weeks (P<.01 for groups
with PBS- and CoPP-pretreated grafts, P< .001 for the
group receiving CoPP-pretreated hESC-CMs plus systemic
CoPP). The protocol using CoPP combination therapy re-
sulted in the highest FS at both 4 and 8 weeks (31.0% 
6.4% and 29.3%  5.0%, respectively), although this
was not statistically different from the 2 other cell therapy
groups (P>.0125).
The primary contributor to the improvement in ejec-
tion fraction was a reduction in end-systolic dimensions
in hearts receiving cell therapy (Figure 4, B). LVESDs
in all treatment groups bettered vehicle-only controls at
4 weeks (each P  .0002). However, by 8 weeks, only
the 2 groups with CoPP-pretreated cells had lower
LVESDs than vehicle-injected groups (each P  .002).
At 8 weeks, differences in LVEDDs between treatment
groups were not statistically significant (P > .0125),
but, nonetheless, hearts in the 2 groups with CoPP-
pretreated cells also had the lowest LVEDDs (data not
shown).
Effects of Systemic CoPP Alone on Functional
Parameters
Weekly doses of CoPP, without cell therapy, also
improved postinfarct ventricular function during ongoingdiovascular Surgery c Volume 148, Number 6 3185
FIGURE 4. Echocardiographic assessment of functional parameters at
baseline, 48 hours, and 4 and 8 weeks after infarction. A, Fractional
shortening (%). Data represent mean values  standard deviations.
*P<.01; **P  .001; ***P  .0001 versus SFM. B, LVESD. Points indi-
cate mean values. Error bars showing standard deviations are limited to the
2 outermost groups so that trends in the mean values can be more easily
visualized. SFM, Infarct injections with serum-free media (vehicle-only
control); LVESD, left ventricular end-systolic diameter; CoPP(r), infarct
recipients treated with systemic cobalt protoporphyrin (CoPP); PBS(g),
graft human embryonic stem cell–derived cardiomyocytes (hESC-CMs)
pretreated with phosphate-buffered saline; CoPP(g), graft hESC-CMs
pretreated with CoPP; CoPP(gþr), graft hESC-CMs pretreated with
CoPP plus recipient treatment with systemic CoPP.
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the group treated with systemic CoPP alone compared to
vehicle-only controls (both P  .0001; Figure 4, A and B).
Notably, at 4 weeks, rats receiving systemic CoPP had a
FS of 30.2%  6.3% compared to only 16.8%  4.3%
in controls given vehicle injections. However, the improve-
ment in FS was a transient one, and lost at 8 weeks (P>
.0125), 1 month after the CoPP dosing had been
discontinued.DISCUSSION
Producing infarct-spanning bridges of neomyocardium,
directionally aligned with the inherent helical myocardial
bands of contraction,1 has the potential to correct postin-
farct ventricular dysfunction in ways that are not currently
possible. However, development of such techniques has3186 The Journal of Thoracic and Cardiovascular Surbeen hampered by the early demise of cells implanted
into infarcts.5-8 To assess the cytoprotective effects of
CoPP pharmacotherapy, hESC-CMs were implanted under
the most adverse conditions—immediately after acute
infarct creation, directly into the infarct center, and into
an infarct with permanent coronary occlusion (without
reperfusion), conditions that have previously precluded
hESC-CM survival. Thus, the most noteworthy conse-
quence of CoPP pretreatment of hESC-CMs was that
76% of the resulting graft area at 8 weeks was found situ-
ated deep within the infarct center, double that of the
PBS-treated cells, making the creation of infarct-spanning
myocardial bridges feasible.
Some recipient groups were also given a course of
systemic CoPP to extend the pharmacologic effects over
the first month after implantation. Hearts receiving the
combined therapy were found to have larger grafts and a
greater extent of infarct replacement by grafted cells
compared to the cell therapy groups without systemic
CoPP, suggesting that continued expression of HO-1 (and
perhaps nrf2-related antioxidants)14,15,21 may have further
stabilized these nascent grafts during infarct maturation.
Populations of surviving native myocytes were also seen
within infarcts in hearts receiving combined therapy. This
was not unexpected, given that induced HO-1 expression
is known to improve native myocyte survival in the face of
ischemia/infarction.16-18 In the present protocol, the
injected CoPP-pretreated cells may have acted as delivery
vehicles for HO-1 within the unvascularized infarct center,
producing early local cytoprotective effects (eg, through
released carbon monoxide) that would also have benefited
resident host cardiomyocytes and endothelial cells.
Importantly, in addition to enhancing graft viability,
injections of CoPP-pretreated hESC-CMs also positively
affected ventricular remodeling in the native heart by
reducing infarct size and LVESD while preserving wall
thickness in the infarct region. Notably, these effects on
remodeling were seen only in groups receiving
CoPP-pretreated hESC-CMs and not in hearts receiving
PBS-pretreated cells. Further, both improvements in infarct
size and wall thickness were even more pronounced when
cell therapy was accompanied by the concomitant course
of systemic CoPP.
All hearts receiving cell therapy were found to have
better ventricular function at 1 and 2 months, with or
without CoPP treatment, compared to hearts with
vehicle-only injections. Thus, the larger graft sizes
and mitigated remodeling seen in hearts receiving
CoPP-supplemented grafts did not translate into advantages
in FS beyond those achieved by cell therapy without CoPP.
However, direct mechanical contributions from these
still-immature cardiomyocytes were not expected at this
time. That said, trends revealed that, by 8 weeks,
ventricular dimensions were stabilizing in the 2 groupsgery c December 2014
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increase in hearts from other groups, suggesting that func-
tional gains might occur over time as these larger
intrainfarct grafts mature and proliferate, especially in
models with graft-host conduction.
Given the known effects of HO-1 overexpression on
postinfarct ventricular function and remodeling,16,19,34
systemic CoPP was given without cell therapy to an
additional control group. In the absence of cell therapy,
systemic CoPP did not alter the infarct size. However,
infarcted hearts exposed to weekly systemic CoPP alone
did exhibit markedly improved FS by 1 month. But, once
systemic CoPP was discontinued, these early gains in
global function were lost by 2 months. In contrast,
improvements in heart function were sustained at 2
months only when the peri-infarction course of systemic
CoPP was combined with cell therapy.
Limitations of the present study are the xenograft model
(without graft-host conduction) and caveats regarding extrap-
olation of rodent data to humans. However, a new report on
infarct repair in nonhuman primate hearts has demonstrated
hESC-CMgraft survival at 3months with electrical coupling
to host cardiomyocytes,35 raising expectations that cellular
transplants can persist and integrate into host ventricles.
If so, such a clinically relevant model could be used to
determine whether structural purposing of cellular grafts by
the proposed strategies would offer long-term functional ad-
vantages. As CoPP alternatives, other less specific, but Food
and Drug Administration–approved, HO-1 inducers (eg,
statins, phosphodiesterase-5 inhibitors) might be explored.
In future clinical applications, such infarct-spanning
‘‘myobridges’’ could be surgically implanted during
coronary artery bypass grafting or minimally invasive
interventions for heart failure. Preprocedural imaging and
predictive simulation modeling might even allow band
orientation to be planned and optimized for individual hearts.
The authors thank Benjamin van Biber for stem cell
preparation, Drs Robert Welikson and Virginia M. Green for
reviewing and editing our manuscript; Dr Jason M. Kim for
assistance with surgical procedures; and Dr Pamela Johnson and
Mary Beauchamp for preparation of the tissue sections.
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hearts. Nature. 2014;510:273-7.MMENTARYCardiac stem cell therapy: Checkered past, promising future?John J. Squiers, BSE,a Kelley A. Hutcheson,MD,b Jeffrey E. Thatcher, PhD,c and J. Michael DiMaio, MDc,dIn this issue of the Journal of Thoracic and Cardiovascular
Surgery (JTCVS), Luo and colleagues1 have demonstrated a
novel approach to transplantation of human embryonic stem
cell grafts within infarcted myocardium in an animal model.
We commend their emphasis on transplanting stem cell
grafts as directionally oriented, infarct-spanning bands.
Often missing from basic science laboratories is the under-
standing of the importance of these macroscopic helical
Torrent-Guasp myocardial bands2 that allow for torsional
deformation of the left ventricle during systole and, thus,
appropriate ventricular function. By submitting their work
to JTCVS, Luo and colleagues recognize that cardiac sur-
geons, who handle the human heart on a near daily basis,
can best appreciate the importance of the heart’s macro-
architecture for effective cardiac function.
Their demonstrated effects of CoPP preconditioning
represent an important step forward in our understanding
of the basic mechanisms and principles underlying regener-
ative stem cell therapy. This bench-top research is crucial toassist clinicians in achieving better clinical outcomes with
cardiac stem cell therapy. In light of this success, however,
it is essential to recognize the often-frustrating discordance
between results of promising basic science research and
more humbling clinical trials over the last 15 years of inves-
tigation into stem cell therapy for cardiac disease.
Extensive research efforts have investigated the potential
for stem cell–mediated cardiac tissue regeneration in the
treatment of cardiovascular disease.3 Early basic science re-
ports suggested enormous therapeutic potential,4 but results
from clinical trials have been disappointing to date. Basic
investigators have employed various kinds of stem cells:
embryonic stem cells (ESCs), induced pluripotent stem
cells (iPSCs), and adult progenitor cells (including skeletal
myoblasts, bone marrow mononuclear cells [BMMNCs],
and cardiac stem cells [CSCs]). So far, however, completed
clinical trials have only reported transplantation of the
various adult progenitor cells. In fact, a casual review of
the clinical trials database (clinicaltrials.gov/ct2/home)
shows that the overwhelming majority of trials has em-
ployed or will employ adult progenitor stem cells rather
than truly pluripotent ESCs or iPSCs.
An early clinical trial of skeletal myoblasts (Myoblast
Autologous Grafting in Ischemic Cardiomyopathy
[MAGIC]5) was discontinued prematurely after both a
lack of efficacy and an increased risk for arrhythmias in pa-
tients receiving stem cell therapy were demonstrated. A
more recent skeletal myoblast trial (ie, SEISMIC6) did not
reveal any effect of stem cell therapy on the left-
ventricular ejection fraction (LVEF). Although BMMNCs
have been the most commonly employed cell type for
stem cell therapy trials (eg, REPAIR-AMI,7 TIME,8
POSEIDON9), these investigations have also yielded
underwhelming results. Meta-analyses of BMMNC trialsgery c December 2014
FIGURE E1. Characterization of cell injectates prior to implantation. Aliquots of differentiated human embryonic stem cell–derived cardiomyocyte
(hESC-CM) injectates were stained with antibodies to (A) cardiac troponin I, denoting cardiomyocytes (green fluorescence); B, Nkx2.5, an early
cardiomyocyte-specific transcription factor (red); or C, Ki67, indicating mitotic cells (red). The nuclei in all panels were counterstained with Hoechst
dye (blue). Scale bars ¼ 50 mm.
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